Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 20/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11917244 | 0.92 | IGF1R (0.46) | IGF1R | |
| SCHEMBL11917265 | 0.92 | NEK1 (0.47) | IGF1R | |
| SCHEMBL11917256 | 0.88 | NEK1 (0.48) | IGF1R | |
| SCHEMBL11917237 | 0.87 | PIK3CA (0.45) | — | |
| SCHEMBL11917243 | 0.84 | IGF1R (0.48) | IGF1R | |
| SCHEMBL11917301 | 0.83 | RET (0.48) | IGF1R | |
| SCHEMBL11917255 | 0.80 | RET (0.47) | — | |
| SCHEMBL11917263 | 0.80 | AURKB (0.47) | IGF1R | |
| SCHEMBL17525309 | 0.76 | NEK1 (0.67) | IGF1R | |
| SCHEMBL11917257 | 0.75 | AURKA (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202818-A1 | UREIDOPHENYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2010144522-A1 | UREIDOPHENYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202818-A1 | UREIDOPHENYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | UCK2, ULK2, ULK1 | IGF1R 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.